# Receptor

> Receptor is a VC fund in New York backing Pharmaceutical and Health Care. See 4 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 4
- Last investment: Sep 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/receptor-partners-llc
- Website: https://www.receptor.vc

Receptor is a VC fund in New York focused on Pharmaceutical and Health Care. Psychedelics will have a significant global impact by introducing novel and effective treatments for depression, addiction, PTSD, anxiety and other mental health disorders. Receptor invests in this new biotech ecosystem through early and mid stage drug discovery companies.

## Contacts

5 contacts available for Receptor. Shizune tracks 1 team members at Receptor. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/receptor-cd70?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Pharmaceutical | 3 | 75% |
| Health Care | 2 | 50% |
| Biotechnology | 2 | 50% |
| Mental Health | 2 | 50% |
| Psychology | 1 | 25% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 50% |
| Pre-Seed | 1 | 25% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Zack Sherman | General Partner | 1 | https://shizune.co/investors/profile/zack-sherman-6076 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MycroDose Therapeutics | Mycrodose Therapeutics is a US-Based pharmaceutical company specialized in the development of advanced drug delivery (ADD) systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. The company is in the parallel development of two of its four core technologies; a psilocybin transdermal delivery system,Ketamine oral mucosa delivery system. |  | Seed | Sep 21, 2021 |  |
| MycroDose Therapeutics | Mycrodose Therapeutics is a US-Based pharmaceutical company specialized in the development of advanced drug delivery (ADD) systems utilizing psychedelic compounds to treat mental health and cognitive degenerative diseases. The company is in the parallel development of two of its four core technologies; a psilocybin transdermal delivery system,Ketamine oral mucosa delivery system. |  | Seed | Sep 21, 2021 |  |
| Mindstate Design Labs | Mindstate Design Labs is a clinical-stage AI neuroengineering platform developing novel psychoactive drug classes for psychiatric disease indications. The company's Osmanthus ensemble of AI models maps the molecular biology of human emotional and cognitive states by integrating the world’s largest datasets of psychoactive pharmacology andsubjective experience. Mindstate's lead program MSD-001 received FDA and EMA approval for Phase I human trials in 2024.Mindstate Design Labs is a Y Combinator company backed by Initialized Capital and other top-tier investors including the founders of OpenAI, Neuralink, Coinbase, Instacart, AngelList, Twitch, and IVADO. The company was founded by biotech venture investor & serial operator Dillan DiNardo and by computer scientist & evolutionary biologist Dr. Thomas Ray, who is famous for instantiating biological phenomena in emergent machine learning systems. | $125K | Pre-Seed | Aug 31, 2021 |  |
| Psilera | Psilera develops therapies aimed at neurological and psychiatric disorders by leveraging neuroplastogens, compounds that promote brain plasticity without hallucinogenic effects. The company builds a proprietary library of serotonergic compounds and applies computational tools to design molecules for conditions such as alcohol use disorder andfrontotemporal dementia. Its research pipeline emphasizes non-hallucinogenic derivatives of psychedelic compounds to provide safe and scalable treatment options. Psilera integrates medicinal chemistry, neuroscience, and pharmacology to create small-molecule drugs that address unmet medical needs. Through this approach, the company seeks to expand treatment possibilities for patients facing hard-to-treat neurological conditions. | $2.5M | Seed | Jul 01, 2021 |  |

4 of 4 investments shown.

## Co-investors
- [Ambria Capital](https://shizune.co/investors/profile/ambria-capital) — VC Fund, 2 deals together
- [Empath Ventures](https://shizune.co/investors/profile/empath-ventures) — VC Fund, 2 deals together
- [K2 & Associates](https://shizune.co/investors/profile/k2-associates) — VC Fund, 2 deals together
- [Negev Capital](https://shizune.co/investors/profile/negev-capital) — VC Fund, 2 deals together
- [Supernode](https://shizune.co/investors/profile/supernode-74b8) — VC Fund, 2 deals together
- [Supernode Ventures](https://shizune.co/investors/profile/supernode-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Receptor invest in?

Receptor invests primarily in Pharmaceutical, Health Care and Biotechnology startups, most often at Seed and Pre-Seed stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Receptor?

Public channels for Receptor include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Receptor?

The team at Receptor includes Zack Sherman (General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co